CTOs on the Move

Tomtec Inc

www.tomtec.com

 
Tomtec Inc is a Hamden, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tomtec.com
  • 1000 Sherman Ave
    Hamden, CT USA 06514
  • Phone: 203.281.6790

Executives

Name Title Contact Details

Similar Companies

Telstar

Telstar is a Trevose, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Crescent City Surgical Centre

Crescent City Surgical Centre is a Metairie, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

bioStrategies Group

bioStrategies Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sellas Life Sciences

Sellas Life Sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. In other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. Our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of Σellas. We strive to improve patients` quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.

Cellarity

Cellarity`s mission is to fundamentally transform the way medicines are created through the development of the first full stack digital cell. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single cell technologies, and machine learning to encode biology, model interventions, and purposefully design breakthrough medicines. By focusing on the cellular changes that underlie disease instead of a single target, Cellarity`s approach uncovers new biology and treatments and is applicable to a vast array of disease areas. The company currently has programs underway in metabolic disease, hematology, immuno-oncology, and respiratory disease. The company has raised $123 million as part of a Series B funding round with contributions from funds and accounts managed by Blackrock, The Baupost Group, Banque Pictet on behalf of their clients, and eight other investors alongside Flagship Pioneering.